Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2026-02-02 @ 9:31 AM
Study NCT ID:
NCT05594758
Status:
AVAILABLE
Last Update Posted:
2024-02-07
First Post:
2022-10-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Named Patient Program for Olverembatinib (HQP1351)
Sponsor:
Ascentage Pharma Group Inc.
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Named Patient Program | View |